<- Go Home
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.
Market Cap
EUR 26.6B
Volume
901.8K
Cash and Equivalents
EUR 1.3B
EBITDA
EUR 3.0B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 5.9B
Profit Margin
25.35%
52 Week High
EUR 52.96
52 Week Low
EUR 35.11
Dividend
2.23%
Price / Book Value
1.35
Price / Earnings
16.99
Price / Tangible Book Value
9.01
Enterprise Value
EUR 37.4B
Enterprise Value / EBITDA
11.05
Operating Income
EUR 2.3B
Return on Equity
8.29%
Return on Assets
3.43
Cash and Short Term Investments
EUR 1.3B
Debt
EUR 11.4B
Equity
EUR 20.4B
Revenue
EUR 23.3B
Unlevered FCF
EUR 2.0B
Sector
Health Care Providers and Services
Category
N/A